Collaboration will support Phase III clinical trial of cell therapy
product ATIR101™ for blood cancers
MINNEAPOLIS & AMSTERDAM–(BUSINESS WIRE)–Be
The Match BioTherapies®, an organization offering
solutions for companies developing and commercializing cell and gene
therapies, and Kiadis
Pharma N.V. (“Kiadis”) (Euronext Amsterdam and Brussels: KDS), a
clinical stage biopharmaceutical company, today announced a strategic
collaboration to support clinical evaluation of an innovative cell
therapy product with potential to make haploidentical hematopoietic stem
cell transplantations (HSCT) safer and more effective for patients.
Under the terms of the collaboration agreement, Be The Match
BioTherapies will provide logistical and technological solutions to
support Kiadis’ Phase III clinical trial for ATIR101, an adjunctive
immunotherapeutic designed to address key risks and limitations of
HSCT in the treatment of blood cancers.
Kiadis’ multinational Phase III clinical trial is evaluating the safety
and efficacy of ATIR101 as an adjunctive treatment to HSCT from a
half-matched (haploidentical) family donor compared to post-transplant
cyclophosphamide (PTCy or “Baltimore” protocol) in adult patients with
blood cancers. The Phase III study is currently enrolling patients in
the EU, Canada, Israel and the U.S.
The collaboration will leverage Be The Match BioTherapies’
industry-leading expertise in cell delivery logistics and supply chain
case management, including the company’s MatchSource®
end-to-end supply chain management software, to manage the transport and
processing of cellular products for use at Kiadis’ clinical trial sites
in the U.S. and Canada.
“Kiadis’ quest to provide better treatment outcomes for patients
receiving stem cell transplants is one we deeply share, given the
foundational role that our parent company, the National Marrow Donor
Program®/Be The Match®, has played in improving
stem cell transplantation for more than three decades,” said Chris
McClain, vice president of Sales and New Business Development, Be The
Match BioTherapies. “We look forward to utilizing our cell therapy
expertise to advance Kiadis’ important work.”
“We’re pleased to partner with Be The Match BioTherapies to progress our
clinical investigation of ATIR101 and to expedite its availability to
patients,” said Andrew Sandler, chief medical officer of Kiadis Pharma.
“We believe this therapeutic approach could allow family members to
serve as stem cell donors for those patients who would otherwise not
find a matching donor in time, ultimately saving lives.”
About Kiadis
Founded in 1997, Kiadis Pharma is a fully
integrated biopharmaceutical company committed to developing innovative
therapies for patients with late-stage blood cancers. With headquarters
in Amsterdam, the Netherlands, Kiadis Pharma is reimagining medicine by
leveraging the natural strengths of humanity and our collective immune
system to source the best cells for life.
Kiadis Pharma is listed on the regulated market of Euronext Amsterdam
and Euronext Brussels since July 2, 2015, under the symbol KDS. Learn
more at kiadis.com.
About ATIR101
ATIR101TM is an investigational
allodepleted T-cell immunotherapy product candidate, which is designed
to be given after a haploidentical (genetically half-matched)
hematopoietic stem cell transplantation (HSCT).
Administered as an adjunctive immunotherapeutic on top of HSCT, ATIR101
provides a single dose donor lymphocyte infusion (DLI) with functional,
mature immune cells from a haploidentical family member. The T-cells in
ATIR101 will help fight infections and remaining tumor cells, until the
immune system has fully re-grown from stem cells in the transplanted
graft.
In ATIR101, T-cells that would cause GVHD are depleted from the donor
lymphocytes, using our photodepletion technology. At the same time,
ATIR101 contains potential cancer-killing T-cells from the donor that
could eliminate residual cancer cells and help prevent relapse of the
disease.
About Be The Match BioTherapies®
Be
The Match BioTherapies is the only cell and gene therapy solutions
provider with customizable services to support the end-to-end cell
therapy supply chain. Backed by the industry-leading experience of the National
Marrow Donor Program®/Be The Match®, and a
research partnership with the CIBMTR® (Center
for International Blood and Marrow Transplant Research®), the
organization designs solutions that advance cell and gene therapies in
any stage of development.
Be The Match BioTherapies is dedicated to providing high-quality
cellular starting material consented for research, clinical and
commercial use, developing and managing expansive cell collection
networks, and navigating cell therapy regulatory compliance. Using
proven infrastructure to successfully manage cell therapy supply chains,
including MatchSource®
Supply Chain Software, dedicated cell therapy supply chain case
managers and logistics experts, the organization has a history of
compliance managing the chain of identity. The collaboration with CIBMTR
extends services to include long-term follow-up tracking for the first
two FDA-approved CAR-T therapies.
For more information, follow Be The Match BioTherapies on LinkedIn or
Twitter at @BTMBioTherapies.
Kiadis Forward-Looking Statements
Certain statements,
beliefs and opinions in this press release are forward-looking, which
reflect Kiadis Pharma’s or, as appropriate, Kiadis Pharma’s directors’
current expectations and projections about future events. By their
nature, forward-looking statements involve a number of risks,
uncertainties and assumptions that could cause actual results or events
to differ materially from those expressed or implied by the
forward-looking statements. These risks, uncertainties and assumptions
could adversely affect the outcome and financial effects of the plans
and events described herein. A multitude of factors including, but not
limited to, changes in demand, regulation, competition and technology,
can cause actual events, performance or results to differ significantly
from any anticipated development. Forward-looking statements contained
in this press release regarding past trends or activities should not be
taken as a representation that such trends or activities will continue
in the future. As a result, Kiadis Pharma expressly disclaims any
obligation or undertaking to release any update or revisions to any
forward-looking statements in this press release as a result of any
change in expectations or any change in events, conditions, assumptions
or circumstances on which these forward-looking statements are based.
Neither Kiadis Pharma nor its advisers or representatives nor any of its
subsidiary undertakings or any such person’s officers or employees
guarantees that the assumptions underlying such forward-looking
statements are free from errors nor does either accept any
responsibility for the future accuracy of the forward-looking statements
contained in this press release or the actual occurrence of the
forecasted developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.
Contacts
Be The Match BioTherapies:
Stephanie Simon
Ten Bridge
Communications
stephanie@tenbridgecommunications.com
+1
(617) 581-9333
Kiadis Pharma:
Maryann Cimino, Manager, Corporate Affairs
m.cimino@kiadis.com
+1
(617) 710-7305